Breaking News
Get 40% Off 0
🔥 This hedge fund gained 26.16% in the last month. Get their top stocks with our free stock ideas tool. See stock ideas
Close

Janone Inc (JAN)

Create Alert
New!
Create Alert
Website
  • As an alert notification
  • To use this feature, make sure you are signed-in to your account
Mobile App
  • To use this feature, make sure you are signed-in to your account
  • Make sure you are signed-in with the same user profile

Condition

Frequency

Once
%

Frequency

Frequency

Follow Janone's earnings

Delivery Method

Status

Add to/Remove from a Portfolio Add to Watchlist
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 
3.175 +0.225    +7.63%
14:54:00 - Real-time Cboe. Currency in USD ( Disclaimer )
Type:  Equity
Market:  United States
  • Volume: 48,613
  • Bid/Ask: 0.000 / 0.000
  • Day's Range: 3.030 - 3.260
Janone 3.175 +0.225 +7.63%

JAN News

 
This page features the latest news about the Janone share.
JanOne set to acquire blockchain fintech firm ALT 5 Sigma
JanOne set to acquire blockchain fintech firm ALT 5 Sigma By Investing.com - May 10, 2024

LAS VEGAS - JanOne Inc. (NASDAQ: JAN), a company recognized for its efforts to combat the opioid crisis, has announced a definitive agreement to acquire ALT 5 Sigma Inc., a provider of blockchain...

JanOne regains Nasdaq compliance with bid price
JanOne regains Nasdaq compliance with bid price By Investing.com - Mar 15, 2024

LAS VEGAS - JanOne Inc. (NASDAQ: JAN), a biopharmaceutical company, has successfully regained compliance with Nasdaq's minimum bid price requirement, according to a notification received from the...

JanOne Files $100M Mixed Shelf
JanOne Files $100M Mixed Shelf By Investing.com - Apr 18, 2024

JanOne (JAN) has filed $100,000,000 mixed shelf of: Common Stock Preferred Stock Debt Securities Warrants Rights Units

JanOne Regains Nasdaq Compliance
JanOne Regains Nasdaq Compliance By Investing.com - Mar 15, 2024

JanOne (Nasdaq: JAN), the biopharmaceutical company focused on developing non-addicting painkillers and novel treatments for the causes of pain, today announced that on March 13, 2024 it received a...

JanOne Announces 899K Share Offering at $0.88/sh
JanOne Announces 899K Share Offering at $0.88/sh By Investing.com - Aug 21, 2023

JanOne (Nasdaq: JAN) (the "Company"), a biopharmaceutical company specializing in developing non-addicting pain killers and treatments for underlying causes of pain, today announced that it has...

JanOne Completes Pre-IND Meeting with FDA on Jan123
JanOne Completes Pre-IND Meeting with FDA on Jan123 By Investing.com - Apr 18, 2023

JanOne (Nasdaq: JAN), the biopharmaceutical innovator specializing in non-addicting painkillers and new treatments for the causes of pain, has completed a successful pre-IND meeting with the FDA...

JanOne Appoints John Bonfiglio to its Board
JanOne Appoints John Bonfiglio to its Board By Investing.com - Mar 23, 2023

JanOne (Nasdaq: JAN), a biopharmaceutical company specializing in developing non-addicting pain killers and treatments for underlying causes of pain, announced the hiring of John N. Bonfiglio, PhD, as...

JanOne Announces 361K Share Direct Offering at $1.17/sh
JanOne Announces 361K Share Direct Offering at $1.17/sh By Investing.com - Mar 23, 2023

JanOne (Nasdaq: JAN), a biopharmaceutical company specializing in developing non-addicting pain killers and treatments for underlying causes of pain, today announced that it has entered into a...

Comment Guidelines

We encourage you to use comments to engage with users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind: 

  • Enrich the conversation
  • Stay focused and on track. Only post material that’s relevant to the topic being discussed.
  • Be respectful. Even negative opinions can be framed positively and diplomatically.
  •  Use standard writing style. Include punctuation and upper and lower cases.
  • NOTE: Spam and/or promotional messages and links within a comment will be removed
  • Avoid profanity, slander or personal attacks directed at an author or another user.
  • Don’t Monopolize the Conversation. We appreciate passion and conviction, but we also believe strongly in giving everyone a chance to air their thoughts. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.

JAN Comments

Write your thoughts about Janone Inc
 
Are you sure you want to delete this chart?
 
Post
Post also to:
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
 
Are you sure you want to delete this chart?
 
Post
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Report this comment

I feel that this comment is:

Comment flagged

Thank You!

Your report has been sent to our moderators for review
Continue with Google
or
Sign up with Email